Form 4: Avidity Biosciences Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, sold shares to cover tax obligations related to vesting of restricted stock units.
Summary
- Teresa McCarthy, Chief Human Resources Officer at Avidity Biosciences, sold a total of 2,959 shares of common stock on January 21, 2025.
- The sales were executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs) on January 20, 2025.
- The shares were sold in multiple transactions at weighted average prices of $28.5931 and $28.5968.
- The sales were not discretionary trades but were mandated by the company's equity incentive plan.
- The reporting person has an instruction letter for automatic 'sell-to-cover' transactions under Rule 10b5-1.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance or outlook.
Industry Context
This is a routine transaction related to executive compensation and is common practice for companies with equity-based compensation plans. It does not indicate any change in the company's outlook or performance.
Comparison to Industry Standards
- The use of 'sell-to-cover' transactions to manage tax obligations on vesting equity is a standard practice across the industry.
- Many companies use similar mechanisms to allow employees to manage their tax liabilities without requiring them to sell shares on the open market at their discretion.
- The price range of the transactions is within the normal range of market fluctuations for a company of this size and sector.
Stakeholder Impact
- The stock sales have a minimal impact on shareholders as they are part of a routine process and do not represent a significant change in ownership.
Key Dates
| Date | Description |
|---|---|
| 01/20/2025 | Restricted stock units (RSUs) vested. |
| 01/21/2025 | Shares sold to cover tax obligations. |
| 01/23/2025 | Form 4 filing date. |
Keywords
Avidity Biosciences, stock sale, insider trading, Form 4, tax withholding, restricted stock units, Rule 10b5-1, equity compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.